- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04685603
Dendritic Cell Vaccine to Prevent COVID-19
Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies
Study Overview
Detailed Description
Subjects eligible for treatment will be those who at baseline, are not actively infected with SARS-CoV-2, have no evidence of prior infection with SARSCoV- 2 based on serologic testing, and give informed consent for a vaccination with AV-COVID-19. The patient population will include the elderly and others at higher risk for poor outcomes after COVID-19 infection. For this reason, individuals will not be excluded solely on the basis of age, body mass index, history of hypertension, diabetes, cancer, or autoimmune disease.
After enrolling for screening, subjects will undergo a nasal swab test to exclude active COVID-19 infection and a rapid test for anti-coronavirus antibodies to exclude pre-existing anti-SARS-CoV-2 antibodies. 50 mL of blood will be collected, from which peripheral blood monocytes will be isolated and differentiated into DC before incubation with SARS-CoV-2 S-protein, during which time the protein is digested into 9 to 25 amino acid peptide sequences presented on the dendrites of DC in conjunction with histocompatibility class I and class II molecules. Safety and quality testing will be performed on a small quantity of the batch, and the remaining AV-COVID-19 will be cryopreserved for shipping to the treatment site.
Once the Study Drug is ready, if eligible, the subject will be seen at Study Week-0 for treatment. Prior to injection of the Study Drug, a nasal swab test will be collected to confirm that they are still negative for COVID-19, and blood will be drawn to determine baseline levels of anti-SARS-CoV-2 antibodies. At the treatment site, the product will be thawed and admixed with saline or (saline with GM-CSF), and within 5 hours of thawing, will be injected SC via a 25- gauge needle
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Muhammad Karyana, Dr., MPH
- Phone Number: +62 21 4261088
- Email: mkaryana@gmail.com
Study Locations
-
-
Jawa Tengah
-
Semarang, Jawa Tengah, Indonesia, 50244
- Recruiting
- Rumah Sakit Umum Pusat Dr. Kariadi
-
Contact:
- Muchlis Achsan Udji Sofro, MD, Internis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older,
- in relatively good health with adequate physical and mental function
- including factors associated with in increased risk for medical complications associated with COVID-19 infection or increased risk for exposure to SARS-CoV-2
Exclusion Criteria:
- Active COVID-19 infection by PCR testing
- Pre-existing IgG or IgM SARS-CoV-2 antibodies
- Pregnant, Known hypersensitivity to GM-CSF
- Known active immune deficiency disease or active HIV
- HBV, HCV, On active treatment with corticosteroids or other immunosuppressive agent
- Participated in previous COVID-19 vaccine study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AV-COVID-19 (0.1 mg antigen, 0 mcg GMCSF)
Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: AV-COVID-19 (0.33 mg antigen, 0 mcg GM-CSF)
Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: AV-COVID-19 (1.0 mg antigen, 0 mcg GMCSF)
Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: Experimental: AV-COVID-19 (0.1 mg antigen, 250 mcg GM-CSF)
Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: AV-COVID-19 (0.33 mg antigen, 250 mcg GM-CSF)
Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: AV-COVID-19 (1.0 mg antigen, 250 mcg GM-CSF)
Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: AV-COVID-19 (0.1 mg antigen, 500 mcg GM-CSF)
Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: AV-COVID-19 (0.33 mg antigen, 500 mcg GM-CSF)
Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
EXPERIMENTAL: AV-COVID-19 (1.0 mg antigen, 500 mcg GM-CSF)
Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
|
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of solicited local and systemic reactogenicity adverse events (AEs)
Time Frame: until follow up day 7
|
Percentage of participants with solicited AEs (local, systemic) for 7 days following vaccination by severity score, duration, and peak intensity.
|
until follow up day 7
|
Safety Laboratory Values (Serum Chemistry)
Time Frame: until follow up day 7
|
Safety laboratory values (Serum Chemistry) by FDA toxicity scoring (absolute and change from baseline where identified) at 7 days after each vaccination.
|
until follow up day 7
|
Safety Laboratory Values (Hematology)
Time Frame: until follow up day 7
|
Safety laboratory values (Hematology) by FDA toxicity scoring (absolute and change from baseline where identified) at 7 days after each vaccination.
|
until follow up day 7
|
Frequency of any serious adverse events (SAEs)
Time Frame: until follow up day 365
|
Percentage of participants with serious undesirable effect associated with the use of a medical product in a patient, which consist of death, life-threatening, hospitalization, disability or permanent damage, congenital anomaly/birth defect, required intervention to prevent permanent impairment or damage (devices), dan other serious important medical events
|
until follow up day 365
|
Frequency of any new-onset chronic medical conditions (NOCMCs)
Time Frame: until follow up day 365
|
NOCMCs will be documented from the time of study vaccination through approximately 1 year after study vaccination
|
until follow up day 365
|
Frequency of medically attended adverse events (MAAEs)
Time Frame: until follow up day 365
|
Percentage of participants with MAAEs, defined as AEs that lead to an unscheduled visit to a healthcare practitioner, through Day 365 by MedDRA classification, severity score, and relatedness.
|
until follow up day 365
|
Frequency of Unsolicited AE and Adverse Events of Special Interest (AESIs)
Time Frame: until follow up day 90
|
Percentage of participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, all MAAEs) or AESIs (potential immune-mediated medical conditions or AEs relevant to COVID-19) through the first 90 days by MedDRA classification, severity score, and relatedness.
|
until follow up day 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs)
Time Frame: until follow up day 28
|
Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs through Day 28.
|
until follow up day 28
|
Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs)
Time Frame: until follow up day 28
|
Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs through Day 28.
|
until follow up day 28
|
Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs)
Time Frame: until follow up day 28
|
Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs through Day 28.
SCR is the proportion of participants with ≥4-fold rises in ELISA units.
|
until follow up day 28
|
Neutralizing Antibody Activity Expressed as GMTs
Time Frame: until follow up day 28
|
Neutralizing antibody activity as detected by microneutralization assay (MN) expressed as GMTs at multiple time points through Day 28.
|
until follow up day 28
|
Neutralizing Antibody Activity Expressed as GMFRs
Time Frame: until follow up day 28
|
Neutralizing antibody activity as detected by MN expressed as GMFRs at multiple time points through Day 28.
|
until follow up day 28
|
Neutralizing Antibody Activity Expressed as SCRs
Time Frame: until follow up day 28
|
Neutralizing antibody activity as detected by MN expressed as SCRs at multiple time points through Day 28.
|
until follow up day 28
|
Assessment of Cell-Mediated (T helper 1 [Th1]/T helper 2 [Th2]) Pathways
Time Frame: until follow up day 28
|
Cell-mediated (Th1/Th2) pathways as measured by whole blood (flow cytometry) and/or in vitro peripheral blood mononuclear cell (PBMC) stimulation (eg, enzyme-linked immunospot [ELISpot], cytokine staining) with SARS-CoV-2 rS protein(s) through Day 28.
|
until follow up day 28
|
Optimal dose of SARS-CoV2 antigen and GM-CSF
Time Frame: until follow up month one
|
Measurement of IgG in subject blood after one month
|
until follow up month one
|
Duration of detection IgG and neutralizing antibody againts SARS-CoV-2in blood after vaccination
Time Frame: until follow up month 12
|
Measurement of IgG and neutralizing antibody in subject blood after 12 months
|
until follow up month 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Djoko Wibisono, Dr. Internis, Rumah Sakit Pusat Angkatan Darat (RSPAD) Gatot Soebroto, Jakarta
- Principal Investigator: Muhammad Karyana, National Institute of Health Research and Development
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-COV-P02-ID
- U1111-1263-0568 (OTHER: WHO-UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on AV-COVID-19
-
Aivita Biomedical, Inc.PT AIVITA Biomedika Indonesia; Kariadi Hospital; Central Army Hospital RSPAD...Completed
-
Aivita Biomedical, Inc.National Institute of Health Research and Development, Ministry of Health... and other collaboratorsCompleted
-
Aivita Biomedical, Inc.Withdrawn
-
CureVacCompletedCovid19 | SARS-CoV-2Belgium, Spain, Germany, Argentina, Colombia, Dominican Republic, Mexico, Netherlands, Panama, Peru
-
AstraZenecaCompleted
-
Hasanuddin UniversityChulalongkorn UniversityCompleted
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...CompletedCoronavirus InfectionFrance
-
Melike CengizCompleted
-
AstraZenecaCompleted
-
University of PennsylvaniaPublic Health Management CorporationCompleted